Omega-3 Fatty Acids and ASCVD


The role of omega-3 fatty acids in treating patients with or at high risk of atherosclerotic cardiovascular disease (ASCVD) using the most recent evidence and guideline recommendations.

Speakers: Dave L. Dixon, PharmD, Virginia Commonwealth University School of Pharmacy; Daniel E. Hilleman, PharmD, Creighton University Schoool of Pharmacy and Health Professions; Joseph Saseen, PharmD, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado

Register today at


Pharmacist Learning Objectives

At the conclusion of this activity, learners should be better able to:

  1. Describe the spectrum of large-scale omega-3 fatty acids on ASCVD outcomes trials
  2. Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
  3. Use information on clinical utility of adjuncts to statin therapy to improve management of patients with or at high risk of ASCVD events




Presented by Postgraduate Health Education and Medtelligence and supported by an independent educational grant from Amarin Pharm, Inc.

Learning Level: Level 2
Track: Satellite Symposia
Session Time Slot(s): 
Saturday, March 21
6:30 PM - 9:00 PM
Gaylord National Resort - National Harbor 6-7
ACPE Pharmacist: 0430-9999-20-002-L01-P
CEUs Pharmacist: 0.2
Activity Type: